ENTITY
Walvax Biotechnology Co A

Walvax Biotechnology Co A (300142 CH)

49
Analysis
Health CareChina
Walvax Biotechnology Company Limited develops, manufactures and sells bio-pharmaceutical vaccination products. The Company's products include haemophilus influenzae type b conjugate vaccine and meningococcal group A,C bivalent polysaccharide conjugate vaccine.
more
15 Oct 2019 10:05

Shanghai/​​​Shenzhen Connect Flows: Midea, Luxshare, Walvax

In our weekly Shanghai/Shenzhen Connect Ideas series, we aim to help our investors understand the flow of northbound trades via the Shanghai and...

Logo
417 Views
Share
bullishKweichow Moutai
23 May 2019 15:55

Shanghai/Shenzhen Connect Ideas: Technologies, Porks and Hard Liquors (2019-05-17)

In our weekly Shanghai/Shenzhen Connect Ideas series, we aim to help our investors understand the flow of northbound trades via the Shanghai and...

Logo
557 Views
Share
13 Mar 2019 14:58

CanSino Biologics (康希诺) IPO: Valuation Update (Part 3)

CanSino is a China-based biotechnology company with a focus on vaccine development. In our previous insight (link to Part 1 and Part 2), we have...

Logo
376 Views
Share
04 Apr 2018 21:35

Attractive EM Charts

Emerging markets remain leadership. While many of the world's developed markets in correction or consolidation mode, EM markets continue to remain...

Logo
358 Views
Share
25 Oct 2016 12:40

Key Drivers of Asia's Healthcare Sector

From a demand perspective, Asia’s population is growing as is longevity. On the supply side, Asia’s number of doctors, nurses, hospitals and...

Share
x